ClinicalTrials.gg
RecruitingNCT06219083NCOMUpdated May 12, 2026

Nutritional Status and Clinical Outcomes in Patients With Common Malignancies(NCOM)

An observational study in Cancer, Chemoradiotherapy and Nutrition, Healthy, sponsored by Xiaoqin Luo. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Xiaoqin Luo · Observational

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,538
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter, prospective cohort study investigates the long-term impact of nutritional status on clinical outcomes in cancer patients undergoing treatment in Shaanxi Province, China. It evaluates how malnutrition, dietary patterns, and nutritional interventions affect treatment tolerance, quality of life, and survival. The study tracks dynamic changes in nutritional health and related indicators throughout various stages of chemoradiotherapy, aiming to inform evidence-based strategies for precision nutrition in oncology care.

Read the detailed description

Study Purpose and Objectives:

The Nutritional Status and Clinical Outcomes in Patients with Common Malignancies (NCOM) study aims to assess how nutritional status influences treatment-related complications, functional performance, psychosocial well-being, and long-term survival in cancer patients. By capturing longitudinal data, the study seeks to identify modifiable risk factors and develop predictive models to support personalized nutritional interventions in oncology.

Study Design and Scope:

The study is being conducted at 11 tertiary hospitals across Xi'an, Shaanxi Province, and will recruit a total of 1,538 patients diagnosed with common malignancies. Participants are enrolled within 48 hours of hospital admission and followed at structured intervals over a five-year period: at 1, 2, 3, 6, and 12 months, and then annually. Baseline and follow-up evaluations include demographic data, cancer-specific clinical characteristics, nutritional risk (mPG-SGA, NRS-2002), dietary intake (SDSAT), quality of life (EORTC QLQ-C30), psychosocial health (HADS), physical activity, sleep quality (PSQI), and laboratory biomarkers.

Data Collection and Management:

Standardized procedures are used for anthropometric measurements, clinical assessments, and patient-reported outcomes. Nutritional support in and out of hospital, inflammatory biomarkers, liver and kidney function, and hematological indicators are systematically recorded. All data are managed via REDCap with built-in validation, routine audits, and centralized oversight.

Quality Assurance and Training:

Research personnel at each site undergo rigorous training to ensure consistency in data collection and patient evaluation. Supervisors oversee data quality, coordinate follow-up, and address missing data or protocol deviations.

Ethical Oversight:

The study adheres to the Declaration of Helsinki and was approved by the Ethics Committee of Xi'an Jiaotong University Health Science Center (Approval No. 2022-1373). Written informed consent is obtained from all participants. All personal data are deidentified and securely stored.

Expected Outcomes and Significance:

By establishing the temporal relationships between nutritional status and clinical outcomes, the NCOM study will provide high-quality evidence to support individualized nutrition-focused care. Results are expected to improve early identification of patients at risk, optimize nutritional interventions, reduce treatment-related toxicity, and enhance long-term cancer prognosis.

02

Conditions studied

  • Cancer
  • Chemoradiotherapy
  • Nutrition, Healthy
  • Oncology
  • Clinical Outcomes

Browse trials for

Keywords

  • Chemoradiotherapy
  • Nutritional Status in Cancer Patients
  • Clinical Outcomes of Cancer Treatment
  • Cancer Patient Nutrition
  • Shaanxi Province Cancer Study
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 1,538 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Xiaoqin Luo is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Cancer patients from 20 hospitals in Shaanxi Province undergoing chemoradiotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years and above
  • diagnosed with malignant tumors
  • Scheduled to undergo radiotherapy and/or chemotherapy
  • Clear consciousness, no communication barriers
  • Willing to undergo follow-up, not in a near-death condition

Exclusion criteria

Exclusion Criteria:

  • Patients without a pathological diagnosis of malignant tumors
  • Patients with AIDS
  • Patients with mental or cognitive disorders
  • Patients who have undergone organ transplantation
  • Patients with a less than 12 months
  • Pregnant women
  • Patients currently participating in other clinical intervention studies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,538 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Change in Nutritional Status Assessed by Modified Patient-Generated Subjective Global Assessment (mPG-SGA)

    Longitudinal assessment of nutritional status using the mPG-SGA, a validated tool composed of five sections (weight loss history, dietary intake, symptoms, function/activity, and age). Total scores range from 0 to ≥7 points, with higher scores indicating worse nutritional status. Patients will be classified as: 0-2 = Normal 3-6 = Mild malnutrition ≥7 = Moderate to severe malnutrition.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  2. Change in Nutritional Risk Assessed by Nutritional Risk Screening 2002 (NRS-2002)

    Longitudinal evaluation of nutritional risk using the NRS-2002, which considers disease severity, nutritional impairment, and age. Total score ranges from 0 to ≥7 points. A score of ≥3 indicates nutritional risk and warrants intervention; \<3 indicates no immediate risk.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  3. Change in Global Health Status Score on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Assessment of patients' perceived overall health status using the global health subscale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scores range from 0 to 100, with higher scores indicating better global quality of life.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  4. Change in Functional Scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Evaluation of physical, role, emotional, cognitive, and social functioning domains using the functional scales of the EORTC QLQ-C30. Each domain score ranges from 0 to 100, with higher scores representing better functioning. Each domain will be reported separately.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  5. Change in Symptom Scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Assessment of symptom burden including fatigue, pain, nausea/vomiting, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulty using symptom subscales of the EORTC QLQ-C30. Each symptom is scored separately from 0 to 100, with higher scores indicating worse symptom severity.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  6. Overall Survival (OS) in Cancer Patients

    Overall survival is defined as the time from the date of enrollment to the date of death from any cause. Patients still alive at the last follow-up will be censored. Kaplan-Meier survival analysis and Cox proportional hazards regression will be used to estimate survival and explore associations with baseline and longitudinal nutritional status.

    Time frame: From date of enrollment until death or last follow-up (up to 5 years)

  7. Progression-Free Survival (PFS) in Cancer Patients

    Progression-free survival is defined as the time from enrollment to the first documented disease progression or death from any cause, whichever occurs first. Patients without progression at the time of last follow-up will be censored. PFS will be analyzed using Kaplan-Meier estimates and Cox regression models, stratified by nutritional status.

    Time frame: From date of enrollment until death or last follow-up (up to 5 years)

Secondary outcomes

  1. Serum Total Protein

    Serum total protein concentration (g/L), used to evaluate protein-energy nutritional status. Measured using standard biochemical assays.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  2. Serum Albumin

    Serum albumin concentration (g/L), used to assess visceral protein status and systemic inflammation.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  3. Serum Prealbumin

    Serum prealbumin level (mg/L), an indicator of short-term changes in protein-energy nutritional status.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  4. Serum Transferrin

    Serum transferrin concentration (g/L), a marker of protein status and iron metabolism.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  5. C-Reactive Protein (CRP)

    Serum CRP (mg/L), a marker of systemic inflammation and acute-phase response.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  6. Blood Glucose

    Fasting blood glucose (mmol/L), measured to assess metabolic function and risk of hyperglycemia.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  7. Aspartate Aminotransferase (AST)

    AST concentration (U/L), used as a liver function test and hepatotoxicity marker.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  8. Alanine Aminotransferase (ALT)

    ALT level (U/L), a liver enzyme measured to monitor hepatic injury.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  9. Interleukin-1 (IL-1)

    IL-1 concentration (pg/mL), a pro-inflammatory cytokine indicative of immune and inflammatory activity.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  10. Tumor Necrosis Factor-alpha (TNF-α)

    Tumor Necrosis Factor-alpha (TNF-α) level (pg/mL) measured to assess systemic inflammation and cancer-related cachexia.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  11. Serum Creatinine

    Serum creatinine (μmol/L), measured to evaluate kidney function and treatment-related nephrotoxicity.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  12. Blood Urea Nitrogen

    Blood urea nitrogen (umol/L), used to monitor renal function and protein catabolism.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  13. Total Bilirubin

    umol/LBlood urea nitrogen (umol/L), used to monitor renal function and protein catabolism.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  14. Direct Bilirubin

    Direct (conjugated) bilirubin (μmol/L), used to evaluate biliary obstruction and liver function.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  15. Total Cholesterol

    Total cholesterol level (mmol/L), measured to assess lipid metabolism and nutritional status.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  16. Triglycerides

    Serum triglyceride level (mmol/L), used to evaluate energy reserves and lipid metabolism.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  17. High-Density Lipoprotein Cholesterol (HDL-C)

    HDL-C (mmol/L), assessed as a marker of cardiovascular health and lipid status.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  18. Low-Density Lipoprotein Cholesterol (LDL-C)

    LDL-C (mmol/L), measured as a risk factor for cardiovascular disease and lipid status.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  19. Interleukin-6 (IL-6)

    IL-6 level (pg/mL), a pro-inflammatory cytokine measured to monitor systemic inflammation and cachexia.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  20. Hemoglobin

    Hemoglobin concentration (\*10⁹/L), used to assess anemia and oxygen-carrying capacity.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  21. White Blood Cell Count (Leukocytes)

    Total white blood cell count (\*10⁹/L), measured to monitor immune status and detect infection or myelosuppression.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  22. Neutrophil Count

    Absolute neutrophil count (\*10⁹/L), used to assess infection risk and bone marrow suppression.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  23. Lymphocyte Count

    Lymphocyte count (\*10⁹/L), measured to evaluate immune competence.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  24. Red Blood Cell Count

    Red blood cell count (\*10¹²/L), used to assess erythropoiesis and anemia.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  25. Platelet Count

    Platelet count (\*10⁹/L), measured to evaluate coagulation status and myelosuppression.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  26. Height

    Standing height (cm) measured using a stadiometer with 0.5 cm precision. Values adjusted for presence of ascites, edema, or large tumors.ascites, systemic edema, and huge tumors.

    Time frame: through study completion, an average of 1 year

  27. Body Weight

    Body weight (kg) measured using a calibrated scale with 0.2 kg precision. Values adjusted if ascites or edema are present.

    Time frame: through study completion, an average of 1 year

  28. Body Mass Index (BMI)

    BMI calculated as weight (kg) divided by height squared (m²), recorded to one decimal place.

    Time frame: through study completion, an average of 1 year

  29. Change in Anxiety Symptoms Assessed by Hospital Anxiety and Depression Scale (HADS-A)

    Change in Anxiety Symptoms Assessed by Hospital Anxiety and Depression Scale (HADS-A)

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  30. Change in Depression Symptoms Assessed by Hospital Anxiety and Depression Scale (HADS-D)

    Assessment of depressive symptoms using the HADS-D subscale of the Hospital Anxiety and Depression Scale. Scores range from 0 to 21, with higher scores indicating more severe depression. Results will be analyzed in relation to nutritional status (normal, mild, moderate malnutrition).

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  31. Functional Performance Measured by Karnofsky Performance Status (KPS)

    Functional performance will be evaluated using the Karnofsky Performance Status (KPS) scale, which ranges from 0 to 100. Higher scores indicate better functional ability and independence in daily activities. Longitudinal KPS changes will be assessed in relation to changes in nutritional status over time.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  32. Changes in Sleep Quality Assessed by Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality and disturbances will be evaluated using the Pittsburgh Sleep Quality Index (PSQI), a standardized questionnaire assessing seven components of sleep. Total scores range from 0 to 21, with higher scores indicating poorer sleep quality. PSQI scores will be analyzed in relation to nutritional risk categories and treatment phases.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  33. Changes in Physical Activity Level During Cancer Treatment

    Assessment of leisure-time physical activity levels (mild, moderate, vigorous) and their relationship with nutritional status and cancer treatment response.

    Time frame: Baseline, 1, 2, 3, 6, and 12 months after admission; annually up to 5 years

  34. Changes in Nutrition-Related Knowledge, Attitudes, and Practices (KAP)

    Patients' dietary knowledge, attitudes, and practices will be assessed using a validated Nutrition KAP (Knowledge, Attitude, and Practice) questionnaire. The total score ranges from 0 to 104, with higher scores indicating better nutritional knowledge, more positive attitudes, and healthier dietary behaviors. Longitudinal changes in KAP scores will be evaluated in relation to treatment outcomes.

    Time frame: Baseline, 6 months, and 12 months after admission; annually up to 5 years

  35. Healthcare Utilization and Cost of Nutrition-Related Care

    Evaluation of healthcare utilization related to nutritional care, including total number of hospitalization days, number of ICU admissions, and direct costs associated with enteral and parenteral nutrition support. Metrics will be analyzed in relation to malnutrition risk at baseline and during treatment.

    Time frame: From admission through 30-day post-discharge and annually for 5 years

  36. Incidence of Serious Adverse Events Related to Nutrition or Treatment

    Tracking of serious adverse events potentially related to nutritional support or treatment, including infections, allergic reactions, gastrointestinal distress, and metabolic complications.

    Time frame: Continuously from enrollment through end of study follow-up (up to 5 years)

Other outcomes

  1. Predictive Value of Baseline Nutritional Indicators for 30-Day Clinical Events

    Evaluation of whether baseline nutritional indicators-including mPG-SGA scores and laboratory biomarkers such as albumin, prealbumin, and CRP-predict 30-day clinical outcomes, including mortality, ICU admission, and significant unintentional weight loss (\>5%). Logistic regression will be used for model construction and discrimination.

    Time frame: Baseline to 30 days post-admission

  2. Nutritional Trajectory Typing and Clustering

    Identification of distinct nutritional change trajectories over time using latent class growth analysis (LCGA) and hierarchical clustering based on serial measurements of mPG-SGA and anthropometric data. Trajectories will be used to classify patients into nutritional risk subgroups.

    Time frame: From baseline to 12-month follow-up

  3. Agreement Between Nutritional Screening Tools (mPG-SGA vs. NRS-2002)

    Assessment of the diagnostic agreement, sensitivity, and specificity of two nutritional screening tools-modified Patient-Generated Subjective Global Assessment (mPG-SGA) and Nutritional Risk Screening 2002 (NRS-2002)-in detecting malnutrition risk. Agreement will be evaluated using Cohen's kappa and ROC curve analysis.

    Time frame: Baseline and each scheduled follow-up visit (up to 5 years)

  4. Sociodemographic Determinants of Malnutrition

    Analysis of sociodemographic factors-including income level, education, employment status, and rural vs. urban residence-in predicting baseline malnutrition and nutritional deterioration over time. Multivariable models will be used to explore independent associations.

    Time frame: From baseline throughout study follow-up (up to 5 years)

  5. Patient Adherence to Out-of-Hospital Nutritional Support

    Evaluation of patient-reported adherence to prescribed oral nutritional supplements or enteral/parenteral support regimens after hospital discharge. Adherence data will be collected via structured interviews and compared with clinical outcomes and readmission rates.

    Time frame: Baseline to 12 months post-treatment initiation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Baracos VE. Cancer-associated malnutrition. Eur J Clin Nutr. 2018 Sep;72(9):1255-1259. doi: 10.1038/s41430-018-0245-4. Epub 2018 Sep 5. No abstract available. PubMed 30185853 ↗
  • Muscaritoli M, Corsaro E, Molfino A. Awareness of Cancer-Related Malnutrition and Its Management: Analysis of the Results From a Survey Conducted Among Medical Oncologists. Front Oncol. 2021 May 13;11:682999. doi: 10.3389/fonc.2021.682999. eCollection 2021. PubMed 34055649 ↗
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗
  • Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022 Feb 9;135(5):584-590. doi: 10.1097/CM9.0000000000002108. PubMed 35143424 ↗
  • Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N, Bray F. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023 Feb;72(2):338-344. doi: 10.1136/gutjnl-2022-327736. Epub 2022 Sep 8. PubMed 36604116 ↗
  • Zhou J, Zheng R, Zhang S, Zeng H, Wang S, Chen R, Sun K, Li M, Gu J, Zhuang G, Wei W. Colorectal cancer burden and trends: Comparison between China and major burden countries in the world. Chin J Cancer Res. 2021 Feb 28;33(1):1-10. doi: 10.21147/j.issn.1000-9604.2021.01.01. PubMed 33707923 ↗
  • Argiles JM. Cancer-associated malnutrition. Eur J Oncol Nurs. 2005;9 Suppl 2:S39-50. doi: 10.1016/j.ejon.2005.09.006. PubMed 16437757 ↗
  • Hebuterne X, Lemarie E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014 Feb;38(2):196-204. doi: 10.1177/0148607113502674. PubMed 24748626 ↗
  • Aaldriks AA, van der Geest LG, Giltay EJ, le Cessie S, Portielje JE, Tanis BC, Nortier JW, Maartense E. Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. J Geriatr Oncol. 2013 Jul;4(3):218-26. doi: 10.1016/j.jgo.2013.04.001. Epub 2013 Apr 30. PubMed 24070460 ↗
  • Seo SH, Kim SE, Kang YK, Ryoo BY, Ryu MH, Jeong JH, Kang SS, Yang M, Lee JE, Sung MK. Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. BMC Cancer. 2016 Nov 18;16(1):900. doi: 10.1186/s12885-016-2934-5. PubMed 27863481 ↗
  • Gellrich NC, Handschel J, Holtmann H, Kruskemper G. Oral cancer malnutrition impacts weight and quality of life. Nutrients. 2015 Mar 27;7(4):2145-60. doi: 10.3390/nu7042145. PubMed 25825828 ↗
  • Planas M, Alvarez-Hernandez J, Leon-Sanz M, Celaya-Perez S, Araujo K, Garcia de Lorenzo A; PREDyCES(R) researchers. Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCES(R) study. Support Care Cancer. 2016 Jan;24(1):429-435. doi: 10.1007/s00520-015-2813-7. Epub 2015 Jun 23. PubMed 26099900 ↗
  • Cong MH, Li SL, Cheng GW, Liu JY, Song CX, Deng YB, Shang WH, Yang D, Liu XH, Liu WW, Lu SY, Yu L. An Interdisciplinary Nutrition Support Team Improves Clinical and Hospitalized Outcomes of Esophageal Cancer Patients with Concurrent Chemoradiotherapy. Chin Med J (Engl). 2015 Nov 20;128(22):3003-7. doi: 10.4103/0366-6999.168963. PubMed 26608978 ↗
  • Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Oldervoll L, Ravasco P, Solheim TS, Strasser F, de van der Schueren M, Preiser JC, Bischoff SC. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021 May;40(5):2898-2913. doi: 10.1016/j.clnu.2021.02.005. Epub 2021 Mar 15. PubMed 33946039 ↗
  • Tan S, Meng Q, Jiang Y, Zhuang Q, Xi Q, Xu J, Zhao J, Sui X, Wu G. Impact of oral nutritional supplements in post-discharge patients at nutritional risk following colorectal cancer surgery: A randomised clinical trial. Clin Nutr. 2021 Jan;40(1):47-53. doi: 10.1016/j.clnu.2020.05.038. Epub 2020 Jun 2. PubMed 32563599 ↗
  • Zietarska M, Krawczyk-Lipiec J, Kraj L, Zaucha R, Malgorzewicz S. Chemotherapy-Related Toxicity, Nutritional Status and Quality of Life in Precachectic Oncologic Patients with, or without, High Protein Nutritional Support. A Prospective, Randomized Study. Nutrients. 2017 Oct 11;9(10):1108. doi: 10.3390/nu9101108. PubMed 29019951 ↗
  • Matthews CE, Moore SC, Arem H, Cook MB, Trabert B, Hakansson N, Larsson SC, Wolk A, Gapstur SM, Lynch BM, Milne RL, Freedman ND, Huang WY, Berrington de Gonzalez A, Kitahara CM, Linet MS, Shiroma EJ, Sandin S, Patel AV, Lee IM. Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk. J Clin Oncol. 2020 Mar 1;38(7):686-697. doi: 10.1200/JCO.19.02407. Epub 2019 Dec 26. PubMed 31877085 ↗
  • Prabhu Das I, Baker M, Altice C, Castro KM, Brandys B, Mitchell SA. Outcomes of multidisciplinary treatment planning in US cancer care settings. Cancer. 2018 Sep 15;124(18):3656-3667. doi: 10.1002/cncr.31394. Epub 2018 Sep 14. PubMed 30216477 ↗
  • Ruff SM, Diaz DA, Pitter KL, Hartwell BC, Pawlik TM. Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma. CA Cancer J Clin. 2023 Jul-Aug;73(4):346-352. doi: 10.3322/caac.21779. Epub 2023 Apr 12. No abstract available. PubMed 37046405 ↗
  • Lu Z, Fang Y, Liu C, Zhang X, Xin X, He Y, Cao Y, Jiao X, Sun T, Pang Y, Wang Y, Zhou J, Qi C, Gong J, Wang X, Li J, Tang L, Shen L. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. 2021 Mar 1;39(7):748-756. doi: 10.1200/JCO.20.01254. Epub 2021 Jan 8. PubMed 33417481 ↗
  • Murphy JL, Munir F, Davey F, Miller L, Cutress R, White R, Lloyd M, Roe J, Granger C, Burden S, Turner L. The provision of nutritional advice and care for cancer patients: a UK national survey of healthcare professionals. Support Care Cancer. 2021 May;29(5):2435-2442. doi: 10.1007/s00520-020-05736-y. Epub 2020 Sep 12. PubMed 32918612 ↗
  • Brown TE, Banks MD, Hughes BGM, Lin CY, Kenny LM, Bauer JD. Randomised controlled trial of early prophylactic feeding vs standard care in patients with head and neck cancer. Br J Cancer. 2017 Jun 27;117(1):15-24. doi: 10.1038/bjc.2017.138. Epub 2017 May 23. PubMed 28535154 ↗
  • Ratri DMN, Hamidah KF, Puspitasari AD, Farid M. Video-based health education to support insulin therapy in diabetes mellitus patients. J Public Health Res. 2020 Jul 3;9(2):1849. doi: 10.4081/jphr.2020.1849. eCollection 2020 Jul 3. PubMed 32728588 ↗
  • Bennell KL, Lawford BJ, Keating C, Brown C, Kasza J, Mackenzie D, Metcalf B, Kimp AJ, Egerton T, Spiers L, Proietto J, Sumithran P, Harris A, Quicke JG, Hinman RS. Comparing Video-Based, Telehealth-Delivered Exercise and Weight Loss Programs With Online Education on Outcomes of Knee Osteoarthritis : A Randomized Trial. Ann Intern Med. 2022 Feb;175(2):198-209. doi: 10.7326/M21-2388. Epub 2021 Nov 30. PubMed 34843383 ↗
  • Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, Compher C, Correia I, Higashiguchi T, Holst M, Jensen GL, Malone A, Muscaritoli M, Nyulasi I, Pirlich M, Rothenberg E, Schindler K, Schneider SM, de van der Schueren MA, Sieber C, Valentini L, Yu JC, Van Gossum A, Singer P. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017 Feb;36(1):49-64. doi: 10.1016/j.clnu.2016.09.004. Epub 2016 Sep 14. PubMed 27642056 ↗
  • Loman BR, Luo M, Baggs GE, Mitchell DC, Nelson JL, Ziegler TR, Deutz NE, Matarese LE; NOURISH Study Group. Specialized High-Protein Oral Nutrition Supplement Improves Home Nutrient Intake of Malnourished Older Adults Without Decreasing Usual Food Intake. JPEN J Parenter Enteral Nutr. 2019 Aug;43(6):794-802. doi: 10.1002/jpen.1467. Epub 2018 Nov 22. PubMed 30565718 ↗
  • Elia M, Normand C, Laviano A, Norman K. A systematic review of the cost and cost effectiveness of using standard oral nutritional supplements in community and care home settings. Clin Nutr. 2016 Feb;35(1):125-137. doi: 10.1016/j.clnu.2015.07.012. Epub 2015 Jul 30. PubMed 26309240 ↗
  • Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6. PubMed 27637832 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The study intends to share IPD with other researchers for advancing scientific understanding and improving patient care. The shared data will include anonymized participant information, such as demographic details, clinical outcomes, and treatment responses. The data will be stripped of any identifiers to ensure participant confidentiality.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The data will become available after the publication of the main study results, anticipated to be by the end of 2025. The data will be accessible for a period of five years following this date.

Access criteria: Researchers interested in accessing the data will be required to submit a proposal outlining their intended use of the data, which will be reviewed by the study's principal investigator. Access will be granted based on the scientific merit and ethical considerations of the proposal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2030, 120 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 120 months is above that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2023
First posted
Jan 23, 2024
StartActual
Nov 12, 2020
Primary completionEst.
Dec 1, 2030
CompletionEst.
Dec 1, 2031
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06219083
Lead sponsor
Xiaoqin Luo
Responsible party
Xiaoqin Luo (Professor, Xi'an Jiaotong University) — Sponsor-investigator
First posted
Jan 23, 2024
Start date
Nov 12, 2020
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
May 12, 2026

Study contacts

Xiaoqin Luo, Ph.D
Contact
clyeah@hotmail.com
+8617791547192
Hexiang Yang, Ph.D
Contact
592518222@qq.com
+8617782582639

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion